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OBJECTIVE—Atherosclerosis is prevalent in diabetic patients,
but there is little information on the localization of nonesteriﬁed
fatty acids (NEFAs) within the plaque and their relationship with
inﬂammation. We sought to characterize the NEFA composition
and location in human diabetic atheroma plaques by metabolo-
mic analysis and imaging and to address their relationship with
inﬂammation activity.
RESEARCH DESIGN AND METHODS—Time-of-ﬂight sec-
ondary ion mass spectrometry (TOF-SIMS) was used for metabo-
lomic analysis imaging of frozen carotid atheroma plaques.
Carotid endarterectomy specimens were used for conventional
immunohistochemistry, laser-capture microdissection quantita-
tive PCR, and in situ Southwestern hybridization. Biological
actions of linoleic acid were studied in cultured vascular smooth
muscle cells (VSMCs).
RESULTS—TOF-SIMS imaging evidenced a signiﬁcant increase
in the quantity of several NEFA in diabetic versus nondiabetic
atheroma plaques. Higher levels of NEFA were also found in
diabetic sera. The presence of LPL mRNA in NEFA-rich areas of
the atheroma plaque, as well as the lack of correlation between
serum and plaque NEFA, suggests a local origin for plaque NEFA.
The pattern of distribution of plaque NEFA is similar to that of
MCP-1, LPL, and activated NF-B. Diabetic endarterectomy
specimens showed higher numbers of inﬁltrating macrophages
and T-lymphocytes—a ﬁnding that associated with higher NEFA
levels. Finally, linoleic acid activates NF-B and upregulates
NF-B–mediated LPL and MCP-1 expression in cultured VSMC.
DISCUSSION—There is an increased presence of NEFA in
diabetic plaque neointima. NEFA levels are higher in diabetic
atheroma plaques than in nondiabetic subjects. We hypothesize
that NEFA may be produced locally and contribute to local
inﬂammation. Diabetes 59:1292–1301, 2010
A
therosclerosis is the major cause of death
among diabetic patients, accounting for 50% of
mortality (1). Diabetes-associated atherosclero-
sis has been estimated to affect 5–8% of the
general population and is by itself a major cause of death
and disability in developed countries. Many factors have
been postulated to link both conditions. Among these
factors we ﬁnd the proinﬂammatory and cytotoxic actions
of high glucose levels and the generation of advanced
glycation end products of proteins that may result in
protein dysfunction or activation of the receptor for ad-
vanced glycation end products (2,3). Lipid abnormalities
also contribute to diabetes-associated atherosclerosis and
even to insulin resistance (4). Dyslipidemia is associated
with increased lipolysis and the release of higher amounts
of nonesteriﬁed fatty acids (NEFAs) into the bloodstream
(5). Hyperglycemia creates a feedback loop, increasing
lipolysis (6,7) and leading to a chronic exposure to NEFA.
Plasma NEFAs promote a systemic insulin resistance state
susceptible to being modiﬁed by dietary or therapeutic
intervention using fat-poor diets or hypolipidemic agents
(8). Central obesity has been linked to predisposition to
type 2 diabetes, possibly through an increased lipolysis at
visceral adipose tissue compared with subcutaneous adi-
pocytes (9).
Despite the vast amount of evidence on the role that
elevated serum levels of NEFA play on the development of
vascular damage in diabetes (10), very little is known
about their accumulation on the arterial wall. NEFAs have
been linked to changes in matrix proteoglycans leading to
an increased lipoprotein uptake on the arterial wall (11).
Emerging molecular imaging techniques, such as TOF-
SIMS, rely on direct interfacing between thin tissue slices
and a mass spectrometer as a detector, allowing precise
measurements of previously unknown molecules (12,13).
Cluster TOF-SIMS has a strong bias toward hydrophobic
molecules, displaying high-resolution images of the most
abundant lipids present on the sample surface. Additionally,
minimal manipulation of snap-frozen samples prevents ana-
lyte delocalization, critical for accurate colocalizations, al-
lowing a straightforward integration with other histological
techniques.
We used TOF-SIMS to characterize the presence and
distribution of NEFA in atheroma plaque specimens from
diabetic and nondiabetic subjects. The diabetic plaque
samples had a more severe degree of inﬂammation and a
higher amount of certain NEFA, including linoleic acid.
NEFA colocalized with lipoprotein lipase (LPL) and mono-
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plaques and, in cultured vascular smooth muscle cells
(VSMCs), linoleic acid promoted nuclear factor-B (NF-
B) activation and LPL and MCP-1 expression.
RESEARCH DESIGN AND METHODS
A total of 40 consecutive patients undergoing carotid endarterectomy (70%
carotid stenosis) at the Vascular Surgery Units of Hospital Clínico San Carlos
and Fundacio ´n Jimenez Díaz were studied. The study was approved by the
local ethics committees in accordance with international guidelines, and
informed consent was obtained before enrollment.
Basic patient characteristics are shown in Table 1. There were no differ-
ences between patients with type 2 diabetes and nondiabetic subjects in age,
sex, or prevalence of hypertension, hypercholesterolemia, or smoking. Ath-
erosclerotic plaques obtained during surgery were immediately processed for
further studies. The ﬁrst four diabetic and ﬁrst four nondiabetic subject
samples were snap-frozen immediately and named the “test group” and the
next 32 collected were embedded in parafﬁn and named the “validation
group.” Both groups had similar clinical characteristics. Clinical data from the
TOF-SIMS group are shown in Table 2. Blood samples for biochemical
analysis were drawn before the surgical procedure. NEFAs were determined
using the NEFA C enzymatic assay kit (WAKO, Neuss, Germany).
TOF-SIMS. Samples were kept at 80°C until 10-m slices were cut using a
cryostat (CM1900; Leica) at a constant temperature of 25°C. Tissue sections
were deposited onto a stainless steel plate (15-7PH; Goodfellow) and stored
again at 80°C. After drying under a pressure of a few hPa for 15 min, they
were directly analyzed in a TOF-SIMS V mass spectrometer (IonTof, Germany)
ﬁtted with a bismuth cluster ion source located at the Parque Cientiﬁco de
Barcelona.
The primary ions impinge the surface of the tissue section with a kinetic
energy of 25 keV. The primary ion dose was between 4.7  10
11 and 10
12
ions/cm2. The secondary ions were extracted with 2 keV energy and postac-
celerated to 10 keV just before hitting the detector surface (single-channel
plate followed by a scintillator and a photomultiplier). A low-energy electron
ﬂood gun was activated to neutralize the surface during the analysis. The
effective ion ﬂight path is 2 m using a reﬂectron, and the mass resolution is
6,300 (full width at half-maximum) at a mass-to-charge ratio (m/z) of 35 and
10,000 at 795.7 m/z.
The ﬁeld of view is 8,000  8,000 m
2 (512  512 pixels). The name of the
compounds or the m/z value of the peak centroid, the maximal number of
counts in a pixel, and the total number of counts are written below each
image. The color scales correspond to the interval [0, maximal number of
counts in a pixel].
Mass calibration and ion peak identiﬁcations were performed as has
previously been described (13). Brieﬂy, initial calibration of monatomic
hydrogen was performed, followed by sequential calibration of known mole-
cules up to 882 Da. In this study, we focus only on previously identiﬁed
quasimolecular ions (14). Total arterial wall NEFA was calculated as the mean
of the different NEFA values normalized by the surface of the sample.
Laser capture microdissection. Frozen endartery tissue was sectioned at 10
m and mounted on a slide covered with a polyethylene naphthalate mem-
brane (PALMZeiss Microlaser Technologies). Tissue slices were stained with
hematoxylin-eosin. RNase-free conditions were maintained as completely as
possible.
TOF-SIMS–directed areas of interest were collected by laser microdissec-
tion and pressure catapulting, which was performed using a PALM MicroLaser
system (PALM-Zeiss) containing a PALM MicroBeam (driven by PALM Micro-
Beam software) and a PALM RoboStage. A typical setting used for laser
cutting was a beam size of 30 m and laser strength of 30 mV under a 5
ocular lens.
Dissected artery sections were catapulted directly into 25 l RNAqueous
microlysis solution, and total RNA was isolated according to the manufactur-
er’s recommendations (RNAqueous micro RNA isolation kit, Ambion) and
stored at 80°C until use. Samples from four patients were studied in each
group (diabetic vs. nondiabetic) with at least three areas of interest per
patient, with a total surface of 120,000 m
2.
VSMC cultures. Human aortic VSMCs (CRL-1999; ATCC) were cultured in
Ham’s F-12 supplemented with 10% FBS, 2 mmol/l glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin, ITS (2.5 g/ml insulin from bovine
pancreas, 2.5 g/l human transferrine, and 2.5 ng/ml sodium selenite), and 30
g/ml endothelial growth supplement at 37°C in 5% CO2 as previously
described (15). Cells between passages three and seven were used for all
experiments. Certain experiments were replicated in primary cultures of rat
VSMC.
RNA extraction and real-time quantitative PCR. Total RNA from VSMC
cultures was isolated using TRIzol Reagent (Invitrogen). One microgram of
RNA was reverse transcribed with a High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA). RNA from tissue was isolated as described
above. All real-time PCR reactions were performed on an ABI Prism 7500
sequence detection PCR system (Applied Biosystems) according to the
manufacturer’s protocol using the DeltaDelta Ct method (16). Expression
levels are given as ratios to 18S. Predeveloped primer and probe assays were
obtained for human 18S and MCP-1 and LPL from Applied Biosystems.
Immunohistochemistry. Carotid atherosclerotic plaques were stored in
paraformaldehyde for 24 h and later in ethanol until parafﬁn embedding.
Immunohistochemistry was performed as previously described (17). Primary
antibodies were mouse anti-LPL antibody (Abcam), rabbit anti–MCP-1 anti-
TABLE 1
Baseline clinical characteristics of study participants
Diabetic Nondiabetic P
Age (years) 71  87 2  9N S
Sex (male/female) 16/3 18/3 NS
Hypertension 13/19 11/21 NS
Hypercholesterolemia 14/19 12/21 NS
Smoking 9/19 10/21 NS
Data are means  SD unless otherwise indicated.
TABLE 2
Baseline clinical characteristics of SIMS study participants
Diabetic Nondiabetic P
Age (years) 71  6.6 68.7  8.7 NS
Sex (male/female) 4/0 3/1 NS
Smokers/total 3/4 2/4 NS
Glycemia (mg/dl) 170.5  36.9 77.75  8.2 0.05
Insulin (IU/dl) 26  8 8.75  1.6 0.05
Systolic blood pressure (mmHg) 127.5  14.7 122.5  14.8 NS
Diastolic blood pressure (mmHg) 63.7  9.6 65  3.5 NS
HDL cholesterol (mg/dl) 66.5  28 82  3N S
LDL cholesterol (mg/dl) 46.5  16.5 41  4.6 NS
Plasma cholesterol (mg/dl) 132  42 140  5N S
Plasma triglycerides (mg/dl) 99.8  40 89  24.6 NS
Apolipoprotein A (mg/dl) 104.5  32 106  21 NS
Apolipoprotein B (mg/dl) 58.5  15 65.6  9.2 NS
Plasma NEFA (mg/dl) 24  20.16 14  5.73 NS
Tissue NEFA (area NEFA/plaque size) 0.142  0.012 0.109  0.004 0.05
Plaque size (m
2) 1,835,000  873,500 2,540,000  873,000 NS
Data are means  SD unless otherwise indicated.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1293body (Immugenex), anti-smooth muscle cell 	-actin (1A4; Dako), or anti-
human macrophages (HAM-56; Dako). Negative controls using the
corresponding IgG were included to check for nonspeciﬁc staining.
Computer-assisted morphometric analysis with the Olympus semiauto-
matic image-analysis system Micro Image software (version 1.0 for Windows)
was performed by a pathologist who was blinded to the patient’s group as
previously described (18). Results are expressed as the percentage of positive
staining per square millimeter.
NF-B Southwestern. The distribution and DNA-binding activity of NF-Bi n
situ was detected using a digoxigenin-labeled double-stranded DNA probe
with a speciﬁc NF-B consensus sequence. Competition assays with 100-fold
excess of unlabeled probe were used as negative controls. For colocalization
studies, immunohistochemistry for macrophages was carried out on slides
directly from the ﬁnal wash of the Southwestern histochemistry protocol
without allowing them to dry as previously described (19).
Electrophoretic mobility shift assay. Electrophoretic mobility shift assay
(EMSA) for NF-B DNA binding activity was performed with nuclear protein
extracts from VSMC as previously described (20). The speciﬁcity of the assay
was tested with a 100-fold excess of unlabeled NF-B consensus oligonucle-
otide added to the
32P-labeled probe-binding reaction.
Western blot and ELISA. Equal amounts (30 g) of cell lysate protein were
loaded onto 12.5% polyacrylamide gels, eletrophoresed, and transfered to
nitocellulose membranes. Then, membranes were blocked with 7% milk
powder in TBS-Tween for 1 h and incubated with anti-LPL (goat polyclonal
sc-32382 used at 1:200; Santa Cruz Biotechnology), anti-IB	 (rabbit poly-
clonal sc-371 used at 1:1,000; Santa Cruz Biotechnology) antibodies overnight
at 4°C. Membranes were washed with TBS-Tween and incubated with
anti-goat, anti-mouse, or anti-rabbit antibodies (1:2000) for1ha troom
temperature. The signal was detected using a chemiluminiscence kit (GE
Healthcare). ELISA for MCP-1 (BD Biosciences) detection in culture super-
natant was performed according to the manufacturer’s protocol.
Statistical analysis. Statistical analysis was performed with SPSS for
Windows software package (version 17; SPSS, Chicago, IL). Results are
expressed as means  SD. In vitro experiments were performed at least three
times. Statistical testing was performed with a two-tailed 	 level of 0.05.
Differences between diabetic and nondiabetic endarterectomy samples were
assessed by the Mann-Whitney nonparametric test. Spearman correlation
coefﬁcients were calculated for continuous characteristics.
RESULTS
Increased NEFA in diabetic atherosclerotic plaques.
Atheroma plaque samples subjected to TOF-SIMS imaging
analysis using bismuth clusters as the primary ion source
render multiple secondary ions corresponding with some
of the most abundant metabolites present on their surface
(Fig. 1). Ionization using liquid ion guns is biased toward
more hydrophobic metabolites rendering secondary ions.
Therefore, we focused on surface analysis of lipids and
lipid derivatives.
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FIG. 1. Representative secondary ion images obtained from carotid endarteries obtained from a nondiabetic suject (top panel) and a diabetic
subject (bottom panel) under the irradiation of bismuth cluster ions. From left to right: tissue micrograph (A); palmitate (C16:0) (B);
palmitoleate (C16:1) (C); stearate (C18:0) (D); oleate (C18:1) (E); linoleate (C18:2) (F); image overlay of palmiteleate (red), cholesterol
(green), and triglycerides (blue) (G); phosphate (H), phosphoinositol fragment (I), triglycerides (J), cholesterol (K), and total ion intensity (L).
The ﬁeld of view is 8  8 mm at 15,625 m/pixel. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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phosphate (79 m/z) molecules can be created similarly to
doing so for any conventional histological study. The
presence of phosphate ion correlates with the presence of
biological tissue and is comparable with the optical image
in Fig. 2. Thus, the morphometric measurement of inor-
ganic phosphate can be used to estimate the size of the
specimens. All metabolite measurements are expressed as
the ratio between the metabolite area and phosphate area
in order to normalize size variation. The phosphate area
average value was 1.835 vs. 2.54 e
6  873,000 m
2 in
diabetic versus nondiabetic subjects, respectively (P 
 not
signiﬁcant).
Quantization of the relative abundance of molecules can
be calculated because their ionization efﬁciency is con-
stant for the whole rastering. Signiﬁcant differences be-
tween the molecules in diabetic and nondiabetic atheroma
plaques were found in only 3 of the 16 molecules. These
three molecules were linoleic acid, palmitic acid, and oleic
acid.
The linoleate quasimolecular ion (m/z) was consistently
increased in all diabetic samples analyzed (C18:2) (0.135 
TABLE 3
Most abundant quasimolecular ions identiﬁed in atherosclerotic plaque negative spectrum
Molecule
Negative
spectrum (m/z)
Signal in
diabetic subjects
Signal in
nondiabetic subjects P
Phosphoinositol fragment 223.0051 0.342  0.069 0.277  0.067 NS
Phosphoinositol fragment 241.0147
C16:0 (palmitic acid) 255.2314 0.211  0.036 0.144  0.033 P  0.05
C16:1 (palmitoleic ac) 253.2195 0.043  0.005 0.033  0.010 NS
C16:2 (hexadecadioneic acid) 251.2052 — — NQ
C18:0 (stearic acid) 283.2609 0.213  0.015 0.181  0.008 NS
C18:1 (oleic acid) 281.2486 0.184  0.078 0.106  0.017 P  0.05
C18:2 (linoleic acid) 279.2313 0.135  0.034 0.083  0.013 P  0.05
C20:4 (arachidonic/eicosatetraenoic) 303.2353 — — NQ
Cholesterol 385.3467 0.092  0.028 0.061  0.024 NS
Vitamin E 429.3705 0.019  0.008 0.012  0.005 NS
Coenzyme Q9 795.6320 — — NQ
Phosphatidic acid 675.5013
0.357  0.020 0.319  0.021 NS Phosphatidic acid 701.5270
Triglycerides 829.7789
0.380  0.081 0.236  0.050 NS Triglycerides 857.8163
Data are means  SD unless otherwise indicated. NQ, nonquantitable.
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FIG. 2. LPL and proinﬂammatory cytokine mRNA expression in NEFA-rich areas. A and B: Hematoxilin-stained endarterectomy section for
laser-capture microdissection showing NEFA-rich areas and its internal controls (24). LPL mRNA (C) and MCP-1 mRNA (D) levels (measured by
quantitative reverse-transcription PCR) in NEFA-rich areas (n  4), diabetic VSMC control areas (n  6), and nondiabetic lipid-rich areas (n 
6) (microdissections; means  95% CI; P < 0.05).
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jects, respectively; P  0.05). Also, palmitic acid (C16:0)
(0.211  0.036 vs. 0.144  0.033; P  0.05) and oleic acid
(C18:1) (0.184  0.078 vs. 0.106  0.017; P  0.05) were
signiﬁcantly increased in plaques from the diabetic sam-
ples. As a control, synthetic triglycerides were irradiated
at the ion dose used for analysis. Quantiﬁcation of the
in-source fragmentation rendered a negligible amount of
NEFA (10% of base peak). This effectively ruled out
artifacts in NEFA measurement. The distribution pattern
was similar between the three fatty acids but did not fully
overlap with triglyceride distribution.
Other lipids widely regarded as major players on athero-
sclerotic pathogenesis, such as cholesterol, did not signif-
icantly differ in quantity between diabetic and nondiabetic
samples (Table 3). Furthermore, there were no differences
in triglyceride accumulation (Table 3). Dyslipidemia in
diabetes is mainly characterized by increased plasma
triglyceride and NEFA levels (21,22). To test whether
NEFA plasma levels correlate with arterial wall NEFA, we
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FIG. 3. MCP-1 and LPL protein expression in diabetes. Representative examples of MCP-1 immunohistochemistry staining in a diabetic patient
(A) and a nondiabetic atherosclerotic patient (C) and LPL immunohistochemistry in a diabetic patient (B) and a nondiabetic subject (D).
Magniﬁcation of a highly positive area within the lesion is shown for both stainings. The protein expression shows a signiﬁcant increase in the
diabetic group vs. the nondiabetic for MCP-1 (E) and LPL (F). Vessels form healthy controls did not stain positive (data not shown). *P < 0.05.
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free plasma fatty acids. Total fasting plasma NEFAs were
higher in diabetic than in nondiabetic subjects (24.37 
20.16 vs. 14  5.73 mg/dl, respectively; P  0.05) (Table 1).
We did not ﬁnd any correlation between plasma NEFA and
any of the lipid molecules measured by TOF-SIMS at the
arterial wall (supplemental Table 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0848/DC1). The sum of NEFA present on
the tissue correlated with glycemia but not with NEFA
plasma levels (supplemental Table 1).
Lipoprotein lipase and MCP-1 expression on NEFA-rich
areas. Several lipases promote the release of NEFA from
complex lipids, mainly triglycerides. LPL is the major con-
tributor to fatty acid hydrolysis in muscle and adipose tissue
(23). High LPL expression by foam cells (24) plays a major
role in local NEFA release in atherosclerotic vessels.
We used laser-capture microdissection in slices consec-
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FIG. 4. Inﬂammatory cells in carotid atherosclerotic plaques studied by immunohistochemistry. Consecutive sections were stained for
macrophages (A and C) and T-cells (B and D) on the plaque. Marked reductions in the number of positive cells within the intimae were observed
in the nondiabetic group vs. the diabetic group both for macrophages (C) and T-cells (D). E: Macrophages. F: T-lymphocytes. *P < 0.05.
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FIG. 5. Arterial NF-B activation determined by Southwestern histochemistry. Consecutive sections to those used in TOF-SIMS analysis
(upper-right corner of A) were used for in situ southwestern (A). Purple nucleus indicates activation, showing a similar pattern of distribution.
The measured intensity is similar to that observed in parafﬁn (C and D). The bar graph (E) shows the quantiﬁcation of positive nuclei per
millimeter squared in the lesions. P values refer to comparisons with nondiabetic subjects. Negative control showed no staining. *P < 0.05. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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expression in NEFA-rich areas identiﬁed by TOF-SIMS
imaging (Fig. 2A). A consistent increase (twofold; P 
0.05) in LPL mRNA expression was found in all diabetic
NEFA-rich areas studied (Fig. 2B) in comparison with
nondiabetic NEFA-rich areas and control diabetic NEFA-
poor areas.
The expression of MCP-1 provides an insight into
plaque-associated inﬂammation. MCP-1 mRNA and protein
were quantitated by laser-capture microdissection qPCR
(Fig. 2D) and by immunohistochemistry (Fig. 3A, C, and
E), respectively. MCP-1 mRNA expression was higher in
diabetic NEFA-rich areas (Fig. 2D). Diabetic subjects had
a signiﬁcantly higher percentage of MCP-1–immuno-
stained neointimal area when compared with nondiabetic
subjects (40  5 vs. 23  4%, respectively; P  0.05).
Immunohistochemical analysis of LPL expression was
carried out in parafﬁn-embedded sections; the area immu-
nostained for LPL was markedly higher in diabetic than in
nondiabetic patients (17.1  7.8 vs. 11.8  4.8% of neoin-
timal area; P  0.05) (Fig. 3B, D, and F). Negative controls
did not stain for LPL (not shown).
Macrophage and T-cell inﬁltration in atherosclerotic
lesions. In relation to nondiabetic atherosclerotic sam-
ples, the diabetic group showed a signiﬁcant increase of
the percentage of neointima staining positive for macro-
phages (22  3 vs. 15  3%; P  0.05) (Fig. 4A and C) and
T-cells (4.4  2 vs. 1.8  0.5%; P  0.05) (Fig. 4B and D),
which is consistent with the increased chemokine expres-
sion. Those results are similar to those found in the
literature (25).
NF-B activation colocalizes with NEFA-rich areas.
NF-B activation was localized to NEFA-rich areas by
Southwestern in frozen samples consecutive to those used
for TOF-SIMS, allowing an overlay between them (Fig. 5A
and B). In addition, a higher number of nuclei staining
positive for NF-B activation with Southwestern histo-
chemistry was noted in parafﬁn-embedded diabetic athero-
sclerotic plaques than in nondiabetic subjects (5,140  512
vs. 3,738  316 stained nuclei per mm
2; P  0.05) (Fig.
5C–E). Nuclear staining was absent in negative controls
(not shown).
Linoleic acid activates NF-B in VSMC and upregu-
lates LPL and MCP-1 expression. Additionally, we
tested in cultured VSMC the possible functional relation
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concentrations and NF-B activation and LPL and MCP-1
upregulation. For these studies we chose linoleic acid, the
NEFA with a highest increment in diabetic plaques (60%
increase over that in nondiabetic subjects).
Linoleic acid increased the NF-B DNA-binding activity
in nuclear extracts, as assessed by EMSA (2.2-fold at 90
mol/l linoleic acid; P  0.05) (Fig. 6A and B). Confocal
microscopy conﬁrmed linoleic acid–induced NF-B acti-
vation and nuclear translocation of p65 NF-B (Fig. 6C).
Linoleic acid increased LPL and MCP-1 mRNA and
protein, and this effect was prevented by pretreatment
with 2.5 g/ml parthenolide, an NF-B inhibitor (28,29)
(Fig. 7A–D) (28,29). This suggests that NF-B mediates
linoleic acid actions on VSMC.
DISCUSSION
Our group recently reported the use of TOF-SIMS to study
the cartography of lipids in atherosclerotic plaques (13).
We now report the presence of NEFA-rich areas within
human atherosclerotic plaques. These NEFA-rich areas
are especially prominent in diabetic subjects, and they
colocalize with areas of inﬂammation characterized by
NF-B activation and increased LPL and MCP-1
expression.
The presence of NEFA-rich areas on the inner side of
the endarterectomy specimens and its relation to inﬂam-
mation is a novel ﬁnding, and very little is known about the
mechanism involved. The extent of those NEFA-rich areas
did not correlate with plasma NEFA levels, suggesting a
local origin in the plaque. The distribution pattern of the
three main fatty acids was similar but did not fully overlap
with triglyceride distribution or VLDL deposition (S. Mas,
unpublished observation). This is consistent with the
hypothesis that, in addition to triglycerides, other complex
lipids could act as NEFA precursors. However, we cannot
exclude the possibility of a triglyceride origin of NEFA.
Several lipases such as LPL (30), endothelial lipase (31)
and phospholipase A2 (32,33) activate and release NEFA
on atherosclerotic lesions and contribute to vascular in-
jury. LPL is considered the rate-limiting enzyme for hydro-
lysis of lipoprotein triglycerides (34), and it is likely to be
secreted by macrophages within atherosclerotic lesions
(24,35). The increased expression of LPL in the NEFA-rich
areas suggests that NEFA might be generated locally by
the action of this enzyme as lipid-laden macrophages
become a major source of LPL (35). NEFA presence at the
intima could be considered an indirect marker of macro-
phage inﬁltration. Nonetheless, image overlay shows a
similar but not identical pattern for macrophages and
NEFA, suggesting a contribution of other cell types,
namely VSMC.
Diabetic patients had higher plaque levels of several
NEFA probed (palmitic, linoleic, and oleic acids) despite
cholesterol and triglyceride levels similar to those in
nondiabetic subjects. In addition, diabetic subjects had
evidence for higher plaque inﬂammation (25). Further-
more, NF-B activation and increased expression of
MCP-1 mRNA were noted in NEFA-rich areas. This raises
the question of the relationship between NEFA and inﬂam-
mation that may be bidirectional. LPL may be expressed in
the context of inﬂammation (23). In addition, linoleic acid
activated NF-B and increased the expression of LPL and
MCP-1 in cultured VSMC. Recently, linoleate induction of
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The data are also consistent with the in vivo observation
that an acute elevation of plasma NEFA activates the
NF-B pathway (37) and increases the hepatic expression
of proinﬂammatory cytokines (38). NEFA may also con-
tribute to vascular injury by inducing the synthesis of
proteoglycan core proteins that promote LDL accumula-
tion at the subendothelial layers (11). Very little is known
about fatty acid signal transduction. In different experi-
mental systems, they have been postulated to bind to
toll-like receptors, particularly TLR4 (39,40), peroxisome
proliferator–activated receptor  (41,42), or fatty acid–
binding receptors (43) and to activate protein kinase C 
(44,45). These pathways converge on NF-B activation and
have been linked to inﬂammation and insulin resistance
(30,46).
In conclusion, diabetic atheroma plaques have higher
NEFA content than those from nondiabetic subjects. In
vivo and in vitro experiments suggest that NEFA could be
a key factor in the genesis of inﬂammation at the plaque.
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